The Vanguard Group 13D and 13G filings for Neurocrine Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-06 2:09 pm Purchase |
2025-02-28 | 13G | Neurocrine Biosciences, Inc. NBIX |
The Vanguard Group | 10,129,687 10.150% |
419,359 (+4.32%) |
Filing |
| 2024-02-13 5:09 pm Purchase |
2023-12-29 | 13G | Neurocrine Biosciences, Inc. NBIX |
The Vanguard Group | 9,710,328 9.880% |
370,033 (+3.96%) |
Filing |
| 2023-02-09 11:27 am Purchase |
2022-12-30 | 13G | Neurocrine Biosciences, Inc. NBIX |
The Vanguard Group | 9,340,295 9.720% |
552,304 (+6.28%) |
Filing |
| 2022-02-10 08:27 am Purchase |
2021-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX |
The Vanguard Group | 8,787,991 9.260% |
450,726 (+5.41%) |
Filing |
| 2021-02-10 11:28 am Purchase |
2020-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX |
The Vanguard Group | 8,337,265 8.920% |
20,368 (+0.24%) |
Filing |